Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02561832 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02561832 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 15 participants.
The verdict
NCT02561832, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is an open-label study to assess the safety, tolerability and efficacy of olaparib in combination with carboplatin. There are two parts in this study: Part A, a dose escalation in patients with advanced Human Epidermal Growth Factor 2 (HER-2) negative breast cancer and Part B, a dose expansion in the neoadjuvant treatment of HER-2 negative breast cancer patients with germline Breast Cancer Susceptibility Gene (BRCA)1/2 mutations.
Interventions
- DRUG Cyclophosphamide
- DRUG Carboplatin
- DRUG Olaparib
- DRUG Anthracycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-11-06 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02561832
The ClinicalTrials.gov registry entry for NCT02561832 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02561832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02561832 about?
NCT02561832 is a clinical study titled "A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer". This is an open-label study to assess the safety, tolerability and efficacy of olaparib in combination with carboplatin. There are two parts in this study: Part A, a dose escalation in patients with advanced Human Epidermal Growth Factor 2 (HER-2) negative breast cancer and Part B, a dose expansion ...
What is the current status of trial NCT02561832?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2015-11-06. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT02561832?
The interventions under investigation include: Cyclophosphamide (DRUG), Carboplatin (DRUG), Olaparib (DRUG), Anthracycline (DRUG).
Who is sponsoring clinical trial NCT02561832?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.